Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir (Q33956146)

30 July 2017

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir (English)

1 reference

30 July 2017

1 reference

S Hetherington

1

1 reference

30 July 2017

S McGuirk

2

1 reference

30 July 2017

G Powell

3

1 reference

30 July 2017

A Cutrell

4

1 reference

30 July 2017

O Naderer

5

1 reference

30 July 2017

B Spreen

6

1 reference

30 July 2017

S Lafon

7

1 reference

30 July 2017

G Pearce

8

1 reference

30 July 2017

H Steel

9

1 reference

30 July 2017

1 October 2001

1 reference

30 July 2017

Clinical Therapeutics

1 reference

30 July 2017

23

1 reference

30 July 2017

10

1 reference

30 July 2017

1603-1614

1 reference

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Antiretroviral effect and safety of abacavir alone and in combination with zidovudine in HIV-infected adults. Abacavir Phase 2 Clinical Team

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

A dose-ranging study to evaluate the safety and efficacy of abacavir alone or in combination with zidovudine and lamivudine in antiretroviral treatment-naive subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Mechanisms of drug reactions: the metabolic track

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Role of Drug Disposition in Drug Hypersensitivity: A Chemical, Molecular, and Clinical Perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

The immunologic and metabolic basis of drug hypersensitivities

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Dermatologic complications associated with administration of 2',3'-dideoxycytidine in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Allergy and desensitization to zidovudine in patients with acquired immunodeficiency syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Hypersensitivity of zidovudine: report of a case of anaphylaxis and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Hypersensitivity syndrome associated with zalcitabine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Nevirapine-associated Stevens-Johnson syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Hypersensitivity syndrome associated with efavirenz therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Hypersensitivity reactions during antiretroviral regimens with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Severe adverse cutaneous reactions to drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Nevirapine and rashes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

A controlled trial of nevirapine plus zidovudine versus zidovudine alone in p24 antigenaemic HIV-infected patients. The Dutch-Italian-Australian Nevirapine Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Severe allergic reaction after repeated exposure to indinavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Acute respiratory failure associated with the human immunodeficiency virus (HIV) protease inhibitor indinavir in an HIV-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

New concepts in immunology relevant to idiosyncratic drug reactions: the "danger hypothesis" and innate immune system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Abacavir rechallenge has to be avoided in case of hypersensitivity reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Risk factors for drug allergy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Idiosyncratic drug reactions: the reactive metabolite syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

Severe anaphylactic shock after rechallenge with abacavir without preceding hypersensitivity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2801%2980132-6

7 January 2021

10.1016/S0149-2918(01)80132-6

Identifiers

DOI

1 reference

release_my7q26qrlrbyfmowmszuhl4z54

30 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/my7q26qrlrbyfmowmszuhl4z54

24 November 2022

mapped directly with Wikidata item

1 reference